Bringing Innovation to Light for Patients

Welcome to UroGen®

We are a biopharmaceutical company dedicated to building novel solutions that treat urothelial and specialty cancers.

Our breakthrough therapy and innovative clinical pipeline aim to maximize the potential benefit of local delivery with our novel RTGel™ technology by bringing to patients transformative, nonsurgical approaches to challenging urothelial and specialty cancers—because we believe patients deserve better.

woman on a beach

Our people make us who we are

At UroGen, we're passionate about making a difference for patients with urothelial and specialty cancers—and we know true progress can only be made when diverse minds come together for this common goal.

Learn more about UroGen >
woman on a beach

Our people make us who we are

At UroGen, we're passionate about making a difference for patients with urothelial and specialty cancers—and we know true progress can only be made when diverse minds come together for this common goal.

Learn more about UroGen>

An industry-leading uro-oncology pipeline

Our investigational product candidates put us on the cutting edge of advancing treatments for urothelial and specialty cancers, including non-muscle invasive bladder cancer.

Explore our pipeline>
Hand holding a light bulb
Hand holding a light bulb

An industry-leading uro-oncology pipeline

Our investigational product candidates put us on the cutting edge of advancing treatments for urothelial and specialty cancers, including non-muscle invasive bladder cancer.

Explore our pipeline >
Man and woman in a lab

Our trailblazing therapies

JELMYTO® (mitomycin) for pyelocalyceal solution is the first FDA-approved treatment using our novel RTGel technology. JELMYTO is the first and only treatment of its kind and received breakthrough approval in April 2020.

See our products and solutions >
Man and woman in a lab

Our trailblazing therapies

JELMYTO® (mitomycin) for pyelocalyceal solution is the first FDA-approved treatment using our novel RTGel technology. JELMYTO is the first and only treatment of its kind and received breakthrough approval in April 2020.

See our products and solutions >